L 377202

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596540

CAS#: 207395-85-5

Description: L 377202 is a peptide-doxorubicin conjugate activated by prostate-specific antigen.


Chemical Structure

img
L 377202
CAS# 207395-85-5

Theoretical Analysis

MedKoo Cat#: 596540
Name: L 377202
CAS#: 207395-85-5
Chemical Formula: C65H89N9O25
Exact Mass: 1,395.60
Molecular Weight: 1,396.460
Elemental Analysis: C, 55.91; H, 6.42; N, 9.03; O, 28.64

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 377202; L-377202; L377202; L-377,202; L 377,202; L377,202;

IUPAC/Chemical Name: 5-((2S)-2-(((2S,5S,8S,11S,14S,17S)-11-(3-amino-3-oxopropyl)-8-cyclohexyl-17-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1R,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)-5,14-bis(hydroxymethyl)-19-methyl-3,6,9,12,15-pentaoxo-4,7,10,13,16-pentaazaicosan-2-yl)carbamoyl)-4-hydroxypyrrolidin-1-yl)-5-oxopentanoic acid

InChi Key: CZXGBIFEWYVYJY-BBOLZPAQSA-N

InChi Code: InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32?,35-,36-,37-,38-,39-,40-,42+,47-,52-,53+,65-/m0/s1

SMILES Code: O=C(c1c(OC)cccc12)c3c(O)c4c(C[C@](C(CO)=O)(O)C[C@H]4O[C@H]5C[C@@H]([C@H](O)[C@H](C)O5)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](C6CCCCC6)NC([C@H](CO)NC([C@H](C)NC([C@H]7N(CC(O)C7)C(CCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)c(O)c3C2=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,396.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002 Apr 1;20(7):1874-9. PubMed PMID: 11919247.

2: DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. 2000 Nov;6(11):1248-52. PubMed PMID: 11062536.